CMS NTAP Cost Criterion: Check Device Feasibility Before Building Your Application
Understand CMS’s NTAP cost criterion, standardized charges, MS-DRG selection and CCR assumptions. Start with the free check, then model scenarios and export an executive brief with NTAP Analyzer.

The CMS NTAP cost criterion asks whether estimated charges for inpatient cases using a new technology exceed the applicable CMS threshold. It does not compare a device's selling price with Medicare payment, and it does not establish how much a hospital will receive. For a MedTech team, it is an early feasibility question—not a reimbursement approval.
Before committing to an NTAP application, separate three decisions: which cases your device belongs in, whether their charge evidence supports the cost criterion, and whether the wider application meets CMS requirements. This guide explains the decision map. The device-specific matching, scenario calculations and executive reporting remain inside the NTAP Analyzer.
Start with the right payment setting
New Technology Add-on Payment (NTAP) is an inpatient hospital payment mechanism under Medicare's Inpatient Prospective Payment System (IPPS). It is not outpatient device pass-through payment, a coverage determination or a separate physician fee.
CMS generally pays an IPPS hospital a case-based amount associated with a Medicare Severity Diagnosis Related Group (MS-DRG), subject to hospital and case adjustments. Individual devices are generally not paid separately within that bundle. Physicians' professional services are paid separately under the Physician Fee Schedule; they are not part of the hospital's MS-DRG payment. See the CMS IPPS overview.
A high device price alone therefore does not establish an NTAP opportunity. First confirm the intended inpatient use, relevant procedures and diagnoses, and the payment setting. An outpatient strategy needs a different analysis.
How CMS evaluates the NTAP cost criterion
42 CFR 412.87(b)(3) describes the cost test in terms of estimated charges for discharges involving the technology. CMS uses standardized charges, adjusted for applicable hospital payment factors, and permits a case-weighted approach where a technology spans multiple relevant DRGs. A raw national average is a planning reference, not a complete submission analysis.
Four distinctions matter before you open a spreadsheet.
1. Evaluate charges per case, not annual sales
The comparison concerns cases using the technology, rather than the manufacturer's annual revenue or aggregate device spending. Selling more units does not, by itself, make a below-threshold case exceed the threshold. Case volumes matter when characterizing the population, weighting relevant DRGs and building a commercial opportunity estimate.
2. Include the relevant hospital stay—not only the device
The charge estimate needs to represent the case involving the technology. That may include relevant facility, procedure, supplies and inpatient-stay resources, with changes to standard care considered. If a baseline already includes a device or procedure your product replaces, simply adding the entire new device charge can double count resources. Explain what stays, what is replaced and what changes.
3. Keep charges, costs and payment separate
A hospital's acquisition cost is not its billed charge, and a billed charge is not Medicare reimbursement. A cost-to-charge ratio (CCR) can support a planning conversion between hospital costs and charges, but the appropriate hospital or cost-center evidence matters. A national reference CCR is not every hospital's markup policy.
4. Account for the actual DRG mix
A device description does not determine a final MS-DRG. Diagnoses, procedures, complications and the applicable coding/grouper version can change assignment. Candidate DRGs help frame the analysis; qualified coding review and representative cases establish the defensible population. Do not select only the most favorable DRG or present a single-DRG screen as the full multi-DRG application.
Use the threshold file for the application cycle
CMS publishes specific NTAP application thresholds with the annual IPPS materials. As checked for this article, the FY 2027 IPPS final rule home page links a distinct FY 2028 NTAP application threshold file, including the correction notice.
That same page also lists a separate FY 2027 Table 10 file. Do not assume every file labeled “Table 10” is the right NTAP application threshold source. Verify the file label, fiscal-year purpose, DRG version and correction notice before using a number. The application cycle and the fiscal year of a supporting dataset need not be identical.
The free NTAP threshold check is a starting point for comparing your selected MS-DRG and charge assumption with the published reference. Confirm the year displayed in the tool before interpreting a result.
A small example: why the baseline can change the decision
These three rows are entirely hypothetical; they are not CMS thresholds, hospital observations or a device recommendation. Both scenarios concern the same invented inpatient population.
Swipe horizontally to see all columns.
| Planning element | Scenario A | Scenario B |
|---|---|---|
| Assumed baseline charges excluding the replaced device | $80,000 | $65,000 |
| Assumed incremental device-related charges | $40,000 | $40,000 |
| Estimated case charges versus an invented $110,000 threshold | $120,000: above | $105,000: below |
The device assumption is unchanged, but the conclusion changes when the baseline changes. That is why a favorable screen is not enough: a reviewer will need to know where the baseline came from, whether the cases are comparable and whether replacement effects were handled. The table shows the logic, not a reusable application model.
Where defensible dollar inputs come from
Use a clear source trail for each input rather than allowing a model to invent a dollar value.
- Hospital acquisition cost: a documented expected hospital selling price, contract assumption or hospital purchasing evidence. Distinguish list price from expected acquisition cost.
- Baseline charges: representative claims or hospital evidence, with the population, year and inclusions identified. CMS Medicare Inpatient Hospitals by Geography and Service provides historical national and geographic reference data; average submitted covered charges are not a forecast for your device's future cases.
- CCR and threshold: applicable hospital/cost-center evidence and the correctly labeled CMS application threshold file. Record the source period and any manual override.
The Analyzer's current reference set combines FY 2027 MS-DRG classifications, FY 2028 application thresholds and CY 2024 national Medicare fee-for-service charge data. Its implantable-device CCR reference is a national planning assumption, not a hospital-specific rate or a universal ratio for all device categories. Different source years must remain visible; a newly created DRG may have no directly corresponding historical charge value.
Analyzer suggestions identify candidate DRGs only; the model does not generate dollar values. A user-entered assumption remains an assumption even when the software performs the arithmetic correctly.
Passing the cost screen is not NTAP approval—or a margin guarantee
The traditional pathway also addresses newness and substantial clinical improvement. Certain technologies may qualify for alternative pathways, but the cost criterion still applies. Review the current pathway requirements and deadlines on the CMS NTAP program page; do not infer eligibility from FDA authorization or designation alone.
Eligibility analysis and claim payment are different tasks. 42 CFR 412.88 describes payment for qualifying discharges involving approved technologies. Do not treat an above-threshold result as an add-on award, apply an add-on percentage directly to gross charges or tell a hospital that its margin is protected. Hospital-specific payment and cost modeling requires separate work.
Move from the decision map to a documented scenario
Use the free NTAP threshold check for an initial reference comparison when you already have a DRG and charge assumption.
Use the CMS NTAP Cost Criterion Analyzer™ when you need candidate device-to-DRG matching, a searchable MS-DRG list, CMS reference inputs, editable baseline charges and CCR assumptions, repeated scenario calculations and a Cahir MedTech executive PDF report. The $149 USD one-time session pass includes unlimited calculations and reports during one active session; it is not permanent access. Leaving the session ends access, and a later session requires another pass. Review the page's sign-in and session terms before purchase.
For broader coding, coverage and hospital adoption planning, see our medical device market-access guide. The Analyzer supports a cost-criterion planning discussion; it does not prepare a complete NTAP submission or replace qualified coding and reimbursement review.
NTAP cost criterion: quick answers
Does CMS compare the device price with the NTAP threshold?
No. The cost criterion concerns estimated charges for inpatient cases involving the technology, with CMS standardization and the relevant DRG framework. Device acquisition cost is one input; it is not the threshold comparison by itself.
Can a national CCR establish our hospital's charges?
No. A national reference can support an early sensitivity assumption, but it does not establish a particular hospital's charge policy or cost-center ratio. Replace it with appropriate evidence when available and document the source.
Does higher annual volume help a case pass the cost criterion?
Not simply by increasing total sales. The cost screen concerns case charges. Volume can affect the case-weighted analysis across relevant DRGs and the commercial opportunity, which are different questions.
Does an above-threshold result guarantee NTAP or hospital profit?
No. CMS evaluates the applicable application requirements and makes approval determinations in rulemaking. Payment for approved technologies follows separate rules, and hospital margin depends on hospital-specific payment and costs.
Is the NTAP Analyzer reimbursement advice?
No. Results are planning estimates; CMS makes the final determination in rulemaking. Candidate DRGs and editable reference assumptions require qualified review before an application or commercial reimbursement claim.
Primary sources and applicability
- 42 CFR 412.87: eligibility, standardized charges and relevant DRG weighting.
- CMS NTAP program guidance: pathways, application resources and current deadlines.
- FY 2027 IPPS final rule files and FY 2028 application thresholds: version-specific reference data and corrections.
- CMS inpatient hospital data: historical submitted covered charges, not device-specific future costs.
- CMS IPPS overview and 42 CFR 412.88: hospital payment setting and separate add-on payment rules.
This article is educational guidance, not reimbursement, legal or coding advice. Hypothetical figures are illustrative only. Publication date: November 17, 2026; editorial/source review: November 20, 2026. Verify current CMS materials and technology-specific requirements before acting.
New to a term? See the MedTech regulatory glossary for plain-English definitions.
Follow MedTech Insights
New articles on FDA 510(k) and De Novo pathways, CE Mark and EU MDR, and device reimbursement — sent to your inbox as they publish.

